Ozet, AhmetDane, FaysalAykan, Nuri FarukYalcin, SuayibEvrensel, TurkkanOzkan, MetinKarabulut, Bulent2024-06-122024-06-1220221479-66941744-8301https://doi.org/10.2217/fon-2022-0455https://hdl.handle.net/20.500.14551/22423Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.en10.2217/fon-2022-0455info:eu-repo/semantics/openAccessMetastatic Colorectal CancerPRECONNECT StudyReal-World DataTrifluridine/TipiracilTurkish PopulationNeutropeniaSurvivalArticle182932673276Q3WOS:0008475066000012-s2.0-8514027232736040321Q1